Company Search:
Advanced Search
Sponsored Links
Genmab A/S Company Snapshot
Genmab A/S operates in the Commercial physical research sector. In addition to historical fundamental analyses, the complete report available to purchase compares Genmab A/S with three other miscellaneous service companies in Europe: Galapagos NV of Belgium (2018 sales of 317.85 million Euro [US$348.51 million] of which 88% was R&D), Clinigen Group PLC of the United Kingdom (£381.20 million [US$468.30 million] of which 57% was Unlicensed Medicines), and Genus plc which is also based in the United Kingdom (£470.30 million [US$577.76 million] of which 53% was Operating Genus PIC).

Sales Analysis. Genmab A/S reported sales of 3.03 billion Danish Kroner (US$444.36 million) for the year ending December of 2018. This represents an increase of 27.9% versus 2017, when the company's sales were 2.37 billion Danish Kroner. Sales at Genmab A/S have increased during each of the previous five years (and since 2013, sales have increased a total of 356%).
Company ReportsSubscriptions
Looking For More?
Purchace an In-Depth Report
Genmab A/S
  Stock Performance Chart for Genmab A/S
  Stock Data: Recent Stock Performance:
  Current Price (10/4/2019): 1,331.00
(Figures in Danish Kroner)
1 Week -4.9%   13 Weeks -5.6%  
4 Weeks 10.9%   52 Weeks 34.9%  
Genmab A/S Key Data:
  Ticker: GMAB Country: Denmark
  Exchanges: CPH Major Industry: Commercial Services & Supplies
    Sub Industry: Commercial Physical Research
  2018 Sales 3,025,137,000
(Year Ending Jan 2019).
Employees: 377
  Currency: Danish Kroner Market Cap: 81,891,401,482
  Fiscal Yr Ends: December Shares Outstanding: 61,526,222
  Share Type: Stammaktie Closely Held Shares:
Feedback | Terms and Conditions | Privacy Policy | Site Index
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.